Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you consider a PARP inhibitor in a patient who harbors a germline BRCA mutation who has metastatic HER2 negative gastric cancer?
Related Questions
How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?
Do you regularly incorporate oral cryotherapy in your practice for patients receiving oxaliplatin to decrease the risk of thermal hyperalgesia?
Do you consider ablative radiation therapy for oligometastatic colon cancer with 5 pulmonary lesions responding to chemotherapy?
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
How would you treat an older patient with multiple co-morbidities and borderline performance status with resectable esophageal cancer in light of ESOPEC trial?
In a patient with a mid-esophageal squamous cell carcinoma with tracheal invasion confirmed on bronchoscopy, would you treat with definitive chemo-radiation with curative intent?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
Would you change treatment approach for rectal cancer with an associated intussusception?
How would you manage a middle thoracic esophageal squamous cell carcinoma (tumor is 25-30 cm from carina) with a positive supra-clavicular lymph node?
In a patient with metastatic gastric cancer with high PDL-1 CPS score (10), at what point, if any, would you consider omitting chemotherapy and continuing immunotherapy alone based on CHECKMATE 649 if patient has a favorable or complete response?
